Biotek-snakken — November 2021
-
Ved ikke om der står noget i prospektet som kom i går aftes https://www.streetinsider.com/SEC+Filings/Form+F-1A+Evaxion+Biotech+AS/19150340.html
-
-
Evaxion fortsætter op i premarket +241%…mystisk
https://www.nasdaq.com/market-activity/stocks/evax/pre-market -
-
The ZW49 program continues to advance in the weekly and once every three week dosing schedules. Expansion cohorts evaluating 2.5 mg/kg every three weeks have enrolled 29 patients and are expected to complete enrollment (30 patients) prior to year end. In parallel, the weekly dose regimen has enrolled 14 patients and continues to dose escalate as the maximum tolerable dose has not been reached. No dose-limiting toxicities have been observed to date. The results of these studies will inform the re
-
Zanidatamab Plus Chemotherapy in Late-Line Breast Cancer to be Presented at San Antonio Breast Cancer Symposium
The presentation will feature new clinical data for zanidatamab, in combination with chemotherapy, as a late-line treatment for patients with HER2-positive breast cancer. The presentation will be available on Wednesday, December 8, 2021. -
Ja, Avanza hælder 10-15.000 aktier ud hver dag….det kan kursen ikke holde til
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind